About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our group is interested in dissecting new cellular signaling pathways that control cancer cell proliferation and differentiation. We collaborate with academics and Biopharma Companies to perform preclinical development of new anticancer drugs. Specifically, we are interested in deciphering the role of the new MAP kinase ERK5 in cancer proliferation and survival. We are also interested in the modulation of autophagy and endoplasmic reticulum (ER) stress as new strategies to tackle cancer, to improve chemotherapy and immunotherapy treatments.
We are involved in potentiating translational aspects of our resources. We actively collaborate with Ability Pharmaceuticals SL in the preclinical/clinical development of the new antitumor drug ABTL0812, which it is Clinical Trial Phase II to treat cancer patients with advanced endometrial and squamous NSCLC cancers (NCT02201823). We uncovered the mechanism involved in the antitumor action of ABTL0812: by modulating the Akt/mTORC1 axis and ER stress, this molecule induces cancer cell death by activating cytotoxic autophagy in cancer cells.
PMID: 32397857 Journal: Autophagy Year: 2021 Reference: Autophagy. 2021 Jun;17(6):1349-1366. doi: 10.1080/15548627.2020.1761651. Epub 2020 May 25. Impact factor: 16.016 Publication type: Paper in international publication Authors: Domenech, Carles, Fabrias, Gemma, Velasco, Guillermo, Lizcano, Jose M, Alfon, Jose, Oaknin, Ana, Romeo, Margarita, Munoz-Guardiola, Pau, Casas, Josefina, Megias-Roda, Elisabet et al. DOI: 10.1080/15548627.2020.1761651
PMID: 33634751 Journal: Autophagy Year: 2021 Reference: Autophagy. 2021 Jan;17(1):1-382. doi: 10.1080/15548627.2020.1797280. Epub 2021 Feb 8. Impact factor: 16.016 Publication type: Review in international publication Authors: Arroyo, Daniela S, Agarwal, Anupam, Aggarwal, Bharat B, Agnello, Maria, Agostinis, Patrizia, Agrewala, Javed N, Agrotis, Alexander, Aguilar, Patricia V, Ahmad, S Tariq, Ahmed, Zubair M et al. DOI: 10.1080/15548627.2020.1797280
On World Cancer Research Day, we highlight research aimed at improving treatments for both pediatric and adult cancers through innovative techniques.
The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.
A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.
